Cargando…

S123: SAFETY AND EFFICACY OF EARLY-START DEFERIPRONE IN INFANTS AND YOUNG CHILDREN WITH BETA-THALASSEMIA (START STUDY)

Detalles Bibliográficos
Autores principales:	Elalfy, M, El-Beshlawy, A, Adly, A, Ebeid, F, Fradette, C, Lee, D, Temin, N, Tricta, F, Rozova, A, Hamdy, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811868/ http://dx.doi.org/10.1097/01.HS9.0000821460.57070.77

Ejemplares similares

P1558: EARLY-START DEFERIPRONE IN INFANTS/YOUNG CHILDREN WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA: EVIDENCE FOR IRON SHUTTLING TO TRANSFERRIN—RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (START)
por: Tricta, F., et al.
Publicado: (2022)

S115: LONG-TERM EFFICACY AND SAFETY OF DEFERIPRONE FOR PATIENTS WITH SICKLE CELL DISEASE OR OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS
por: Inusa, B, et al.
Publicado: (2022)

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
por: Elalfy, Mohsen S., et al.
Publicado: (2022)

P1442: PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY
por: Badawy, Sherif, et al.
Publicado: (2023)

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study
por: Kwiatkowski, Janet L., et al.
Publicado: (2022)

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease
por: Soulières, Denis, et al.
Publicado: (2022)

P1511: EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH Β-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW
por: Piga, A., et al.
Publicado: (2022)

Deferiprone‐induced agranulocytosis: 20 years of clinical observations
por: Tricta, Fernando, et al.
Publicado: (2016)

Prospective comparison on cardiac iron by MR in thalassemia major patients treated with combination deferipron-desferrioxamine versus deferipron and desferrioxamine in monoterapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Effects of renal impairment on the pharmacokinetics of orally administered deferiprone
por: Fradette, Caroline, et al.
Publicado: (2016)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
por: Chand, Gyan, et al.
Publicado: (2009)

S111: BRAIN PERFUSION CHANGES IN BETA-THALASSEMIA
por: Manara, R, et al.
Publicado: (2022)

Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective
por: Galanello, Renzo
Publicado: (2007)

Treating thalassemia major-related iron overload: the role of deferiprone
por: Berdoukas, Vasilios, et al.
Publicado: (2012)

Preparation for adult participation, starting at the beginning
por: Thibadeau, Judy
Publicado: (2009)

The safety and acceptability of twice‐daily deferiprone for transfusional iron overload: A multicentre, open‐label, phase 2 study
por: Badawy, Sherif M., et al.
Publicado: (2021)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

A T2* MRI prospective survey on heart iron in thalassemia major patients treated with sequential deferiprone-desferrioxamine versus deferipron and desferrioxamine in monotherapy
por: Pepe, Alessia, et al.
Publicado: (2011)

Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy
por: Pepe, Alessia, et al.
Publicado: (2013)

When to start: as soon as possible
por: Saag, M
Publicado: (2012)

When to start: not so fast
por: Lundgren, J
Publicado: (2012)

How early to start: what do observational data suggest?
por: Sterne, J
Publicado: (2010)

Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
por: Smith, Gillian C, et al.
Publicado: (2011)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone
por: Porter, John B, et al.
Publicado: (2013)

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload
por: Alavi, Samin, et al.
Publicado: (2014)

Mobilization exercises in preparation to bracing must be only at start of brace wearing. Results from a prospective controlled study
por: Romano, M, et al.
Publicado: (2012)

Systematic techniques for assisting recruitment to trials (START): developing the science of recruitment
por: Rick, Jo, et al.
Publicado: (2013)

Disorder at the Start: The Contribution of Dysregulated Translation Initiation to Cancer Therapy Resistance
por: Sunavala-Dossabhoy, Gulshan
Publicado: (2021)

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Assessment of patients' and caregiver’s perceived need to start actively participated outcome measures in neurological research
por: Celani, MG, et al.
Publicado: (2015)

S106: LONG-TERM FOLLOW-UP OF BETA-THALASSEMIA PATIENTS TREATED WITH HEMATOPOIETIC STEM CELL GENE THERAPY
por: Marktel, S, et al.
Publicado: (2022)

BET proteins target murine leukemia virus integration to transcription start sites
por: Sharma, Amit, et al.
Publicado: (2013)

Early Predictors of Renal Dysfunction in Egyptian Patients with β-Thalassemia Major and Intermedia
por: Tantawy, Azza A.G., et al.
Publicado: (2014)

StartLink and StartLink+: Prediction of Gene Starts in Prokaryotic Genomes
por: Gemayel, Karl, et al.
Publicado: (2021)

Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia
por: Susanah, Susi, et al.
Publicado: (2020)

Start-up costs of implementing Screening and Brief Intervention (SBI) for Adolescents (part of Economics of SBI symposium)
por: Barbosa, Carolina, et al.
Publicado: (2015)

Start Now
por: Kahn, Jessica A.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ekkl9rpnk52j9bgt40cjvt2qu4